ARYx Therapeutics (OTCPK:ARYX) - Stock Price, News & Analysis

ARYX Stock Overview

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. More details

ARYX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Latest financial reports are more than a year old

High level of non-cash earnings

Does not have a meaningful market cap ($33)

ARYx Therapeutics, Inc. Competitors

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

MJ Holdings

OTCPK:MJNE

US$58.0

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$111.0

Price History & Performance

Summary of all time highs, changes and price drops for ARYx Therapeutics
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-99.96%
5 Year Change	-99.98%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ARYX	US Pharmaceuticals	US Market
7D	0%	3.4%	1.6%
1Y	n/a	14.2%	32.3%

Return vs Industry: Insufficient data to determine how ARYX performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ARYX performed against the US Market.

Price Volatility

Is ARYX's price volatile compared to industry and market?
ARYX volatility
ARYX Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ARYX has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ARYX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	n/a	n/a	n/a

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat.

ARYx Therapeutics, Inc. Fundamentals Summary

How do ARYx Therapeutics's earnings and revenue compare to its market cap?
ARYX fundamental statistics
Market cap	US$33.00
Earnings (TTM)	-US$18.33m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ARYX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARYX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$18.33m
Earnings	-US$18.33m

Last Reported Earnings

Sep 30, 2010

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ARYX perform over the long term?

See historical performance and comparison